Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

electroCore

From Wikipedia, the free encyclopedia

electroCore, Inc. (Nasdaq: ECOR) is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD.[1] The current chief executive officer is Daniel S. Goldberger.[2] electroCore[3] has one product called gammaCore,[4][5] a non-invasive, commercially available product that uses vagus nerve stimulation.[6]

History

[edit]

The company was co-founded by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD, in 2005.[1]

In 2018, electroCore, Inc. went public with a $78 million IPO.[7]

On March 27, 2020, electroCore announced a common stock purchase agreement of up to $25 million with Chicago-based institutional investor Lincoln Park Capital Fund, LLC.[8]

In 2025, the company acquired NeuroMetrix, adding the Quell electrical nerve stimulation platform to its product portfolio.[9]

Products

[edit]

gammaCore Sapphire CV

[edit]

In July 2020, the FDA gave an emergency COVID-19 authorization for gammaCore Sapphire CV, a vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma.[10]

Truvaga

[edit]

A VNS product owned by Electrocore.[11]

References

[edit]
  1. 1 2 "electroCore Inc. Company & People | ECOR". Barron's. Retrieved 2024-12-12.
  2. "Nerve stimulation device maker electroCore goes public with $78M IPO | FierceBiotech". www.fiercebiotech.com. Retrieved 2019-03-06.
  3. "This hand-held device is approved to treat cluster headaches". NBC News. Retrieved 2019-03-06.
  4. "ElectroCore wins cluster headache FDA 510(k) indication for GammaCore". MassDevice. 2018-11-28. Retrieved 2019-03-06.
  5. "Nerve Stimulator Approved for Cluster Headache". Pain News Network. Retrieved 2019-03-06.
  6. "Term Sheet -- Friday, June 22". Fortune. Retrieved 2019-03-06.
  7. Hale, Conor (2018-06-22). "Nerve stimulation device maker electroCore goes public with $78M IPO | Fierce Biotech". www.fiercebiotech.com. Retrieved 2024-12-16.
  8. "BRIEF-electroCore Announces Common Stock Purchase Agreement For Up To $25 Mln With Lincoln Park Capital". Reuters. 2020-03-27. Retrieved 2020-03-31.
  9. Hale, Conor (2024-12-20). "ElectroCore buys NeuroMetrix and its Quell fibromyalgia wearable". www.fiercebiotech.com. Retrieved 2026-07-22.
  10. electroCore (2020-07-13). "electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients". GlobeNewswire News Room. Retrieved 2020-07-15.
  11. https://www.truvaga.com/vagus-nerve-science/